News

Late on Friday, Sarepta refused an FDA request to voluntarily halt shipments of Elevidys—a request made after it first surfaced in news reports, the company said in a statement. “Based on our ...
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...